Last updated on November 2019

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).


Find a site near you

Start Over

Novartis Investigative Site

Itabashi-ku, Japan
2.35miles
  Connect »